KZIA · Kazia Therapeutics Limited

Kazia Therapeutics has strategically expanded its oncology platform through the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. This transaction represents a significant pipeline expansion that addresses a major unmet need in oncology—immune resistance in aggressive, treatment-refractory cancers. The SETDB1 program targets a key epigenetic regulator of tumor immune evasion that has been associated with poorer clinical outcomes in several tumor types. By inhibiting SETDB1, the approach aims to restore interferon signaling, enhance antigen presentation, and increase tumor immune recognition, potentially making resistant tumors responsive to immunotherapy again. The lead candidate MSETC, discovered using an AI-integrated epigenetic drug discovery engine, is a highly selective bicyclic peptide designed to target a novel, disease-associated nuclear SETDB1 complex. Financially, the transaction involves modest upfront capital commitment with a tiered revenue-sharing structure that aligns with development progress, providing capital efficiency. Kazia plans to advance both the SETDB1 program and its PD-L1 degrader platform in parallel through IND-enabling studies, leveraging shared resources to achieve execution efficiencies. The combined cost of approximately $6 million over 18 months for both programs represents disciplined capital allocation, with a substantial portion expected to qualify for Australian R&D tax incentives. This expansion positions Kazia's pipeline across three complementary layers of cancer control—chromatin-level regulation with SETDB1, transcriptional reprogramming with paxalisib, and protein-level control with the PD-L1 degrader platform—creating opportunities for combination therapies across multiple cancer types. The company sees strong partnering potential for the SETDB1 program given its broad applicability across tumor types and role in immune resistance.